APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia Gene Therapy

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

Selected research

Market Structure

Global Hemophilia Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025184 pages

Choose your research edition.

Industry ResearchHemophilia Gene Therapy Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia Gene Therapy Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Hemophilia Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia Gene Therapy Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia Gene Therapy Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.

Report Includes

Read the full market overview

This report provides an overview of the global Hemophilia Gene Therapy market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hemophilia Gene Therapy and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hemophilia Gene Therapy revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Hemophilia Gene Therapy market size, projected growth trends, production technologies, key applications, and end-use industries.

Hemophilia Gene Therapy Segment by Company

Spark Therapeutics

Ultragenyx

Shire PLC

Sangamo Therapeutics

Bioverativ

BioMarin

uniQure

Freeline Therapeutics

Hemophilia Gene Therapy Segment by Type

Hemophilia A

Hemophilia B

Hemophilia Gene Therapy Segment by Application

Hemophilia A Gene Therapy

Hemophilia B Gene Therapy

Hemophilia Gene Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Hemophilia Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hemophilia Gene Therapy industry.

Chapter 3: Detailed analysis of Hemophilia Gene Therapy companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemophilia Gene Therapyrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hemophilia Gene Therapy Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Hemophilia A Table 3. Key Players of Hemophilia B Table 4. Global Hemophilia Gene Therapy Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hemophilia A Gene Therapy Table 6. Key Players of Hemophilia B Gene Therapy Table 7. Global Hemophilia Gene Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global Hemophilia Gene Therapy Market Size by Region (2021-2026) & (US$ Million) Table 9. Global Hemophilia Gene Therapy Market Share by Region (2021-2026) Table 10. Global Hemophilia Gene Therapy Market Size by Region (2027-2032) & (US$ Million) Table 11. Global Hemophilia Gene Therapy Market Share by Region (2027-2032) Table 12. Hemophilia Gene Therapy Industry Trends Table 13. Hemophilia Gene Therapy Industry Drivers Table 14. Hemophilia Gene Therapy Industry Opportunities and Challenges Table 15. Hemophilia Gene Therapy Industry Restraints Table 16. Global Hemophilia Gene Therapy Revenue by Company (US$ Million) & (2021-2026) Table 17. Global Hemophilia Gene Therapy Revenue Market Share by Company (2021-2026) Table 18. Global Hemophilia Gene Therapy Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global Hemophilia Gene Therapy Key Company Head Office and Area Served Table 20. Global Hemophilia Gene Therapy Company, Product Type & Application Table 21. Global Hemophilia Gene Therapy Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global Hemophilia Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global Hemophilia Gene Therapy Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hemophilia Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 26. Global Hemophilia Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 27. Global Hemophilia Gene Therapy Revenue Market Share by Type (2021-2026) Table 28. Global Hemophilia Gene Therapy Revenue Market Share by Type (2027-2032) Table 29. Global Hemophilia Gene Therapy Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Hemophilia Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 31. Global Hemophilia Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 32. Global Hemophilia Gene Therapy Revenue Market Share by Application (2021-2026) Table 33. Global Hemophilia Gene Therapy Revenue Market Share by Application (2027-2032) Table 34. Spark Therapeutics Company Information Table 35. Spark Therapeutics Business Overview Table 36. Spark Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Spark Therapeutics Hemophilia Gene Therapy Product Portfolio Table 38. Spark Therapeutics Recent Development Table 39. Ultragenyx Company Information Table 40. Ultragenyx Business Overview Table 41. Ultragenyx Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Ultragenyx Hemophilia Gene Therapy Product Portfolio Table 43. Ultragenyx Recent Development Table 44. Shire PLC Company Information Table 45. Shire PLC Business Overview Table 46. Shire PLC Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Shire PLC Hemophilia Gene Therapy Product Portfolio Table 48. Shire PLC Recent Development Table 49. Sangamo Therapeutics Company Information Table 50. Sangamo Therapeutics Business Overview Table 51. Sangamo Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio Table 53. Sangamo Therapeutics Recent Development Table 54. Bioverativ Company Information Table 55. Bioverativ Business Overview Table 56. Bioverativ Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Bioverativ Hemophilia Gene Therapy Product Portfolio Table 58. Bioverativ Recent Development Table 59. BioMarin Company Information Table 60. BioMarin Business Overview Table 61. BioMarin Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. BioMarin Hemophilia Gene Therapy Product Portfolio Table 63. BioMarin Recent Development Table 64. uniQure Company Information Table 65. uniQure Business Overview Table 66. uniQure Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. uniQure Hemophilia Gene Therapy Product Portfolio Table 68. uniQure Recent Development Table 69. Freeline Therapeutics Company Information Table 70. Freeline Therapeutics Business Overview Table 71. Freeline Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio Table 73. Freeline Therapeutics Recent Development Table 74. North America Hemophilia Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 75. North America Hemophilia Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 76. North America Hemophilia Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 77. North America Hemophilia Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 78. North America Hemophilia Gene Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. North America Hemophilia Gene Therapy Market Size by Country (2021-2026) Table 80. North America Hemophilia Gene Therapy Market Size by Country (2027-2032) Table 81. Europe Hemophilia Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 82. Europe Hemophilia Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 83. Europe Hemophilia Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 84. Europe Hemophilia Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 85. Europe Hemophilia Gene Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. Europe Hemophilia Gene Therapy Market Size by Country (2021-2026) Table 87. Europe Hemophilia Gene Therapy Market Size by Country (2027-2032) Table 88. China Hemophilia Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 89. China Hemophilia Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 90. China Hemophilia Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 91. China Hemophilia Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 92. Asia Hemophilia Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 93. Asia Hemophilia Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 94. Asia Hemophilia Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 95. Asia Hemophilia Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 96. Asia Hemophilia Gene Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Asia Hemophilia Gene Therapy Market Size by Country (2021-2026) Table 98. Asia Hemophilia Gene Therapy Market Size by Country (2027-2032) Table 99. South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Type (2021-2026) & (US$ Million) Table 100. South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Type (2027-2032) & (US$ Million) Table 101. South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Application (2021-2026) & (US$ Million) Table 102. South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Application (2027-2032) & (US$ Million) Table 103. South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2021-2026) Table 105. South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2027-2032) Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Hemophilia Gene Therapy Product Image Figure 2. Global Hemophilia Gene Therapy Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Hemophilia Gene Therapy Market Share by Type: 2025 VS 2032 Figure 4. Hemophilia A Image Figure 5. Hemophilia B Image Figure 6. Global Hemophilia Gene Therapy Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Hemophilia Gene Therapy Market Share by Application: 2025 VS 2032 Figure 8. Hemophilia A Gene Therapy Image Figure 9. Hemophilia B Gene Therapy Image Figure 10. Global Hemophilia Gene Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 12. Global Hemophilia Gene Therapy Market Share by Region: 2025 VS 2032 Figure 13. Years Considered Figure 14. Global Hemophilia Gene Therapy Market Share by Players in 2025 Figure 15. Global Top 5 and 10 Hemophilia Gene Therapy Players Market Share by Revenue in 2025 Figure 16. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Hemophilia Gene Therapy Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Hemophilia Gene Therapy Revenue Market Share by Type (2021-2032) Figure 19. Global Hemophilia Gene Therapy Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Hemophilia Gene Therapy Revenue Market Share by Application (2021-2032) Figure 21. North America Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 22. North America Hemophilia Gene Therapy Market Share by Type (2021-2032) Figure 23. North America Hemophilia Gene Therapy Market Share by Application (2021-2032) Figure 24. North America Hemophilia Gene Therapy Market Share by Country (2021-2032) Figure 25. United States Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 26. Canada Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 27. Mexico Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 28. Europe Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 29. Europe Hemophilia Gene Therapy Market Share by Type (2021-2032) Figure 30. Europe Hemophilia Gene Therapy Market Share by Application (2021-2032) Figure 31. Europe Hemophilia Gene Therapy Market Share by Country (2021-2032) Figure 32. Germany Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 33. France Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 34. U.K. Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 35. Italy Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 36. Russia Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 37. Nordic Countries Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 38. China Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 39. China Hemophilia Gene Therapy Market Share by Type (2021-2032) Figure 40. China Hemophilia Gene Therapy Market Share by Application (2021-2032) Figure 41. Asia Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 42. Asia Hemophilia Gene Therapy Market Share by Type (2021-2032) Figure 43. Asia Hemophilia Gene Therapy Market Share by Application (2021-2032) Figure 44. Asia Hemophilia Gene Therapy Market Share by Country (2021-2032) Figure 45. Japan Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 46. South Korea Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 47. Taiwan Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 48. Southeast Asia Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 49. India Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 50. Australia Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 51. South America, Middle East & Africa Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Hemophilia Gene Therapy Market Share by Type (2021-2032) Figure 53. South America, Middle East & Africa Hemophilia Gene Therapy Market Share by Application (2021-2032) Figure 54. South America, Middle East & Africa Hemophilia Gene Therapy Market Share by Country (2021-2032) Figure 55. Brazil Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 56. South Africa Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 58. Turkey Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 59. Argentina Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 60. UAE Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 61. Egypt Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 62. Chile Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 63. Research Process Figure 64. Key Executives Interviewed

Scope & coverage.

Types
  • Hemophilia A
  • Hemophilia B
Applications
  • Hemophilia A Gene Therapy
  • Hemophilia B Gene Therapy
Companies covered
  • Spark Therapeutics
  • Ultragenyx
  • Shire PLC
  • Sangamo Therapeutics
  • Bioverativ
  • BioMarin
  • uniQure
  • Freeline Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Hemophilia Gene Therapy Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Hemophilia A
  5. 1.2.3 Hemophilia B
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Hemophilia Gene Therapy Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Hemophilia A Gene Therapy
  9. 1.3.3 Hemophilia B Gene Therapy
  10. 1.4 Global Market Growth Prospects
  11. 1.5 Global Hemophilia Gene Therapy Growth Trends by Region
  12. 1.5.1 Global Hemophilia Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
  13. 1.5.2 Hemophilia Gene Therapy Market Size by Region (2021-2026)
  14. 1.5.3 Hemophilia Gene Therapy Market Size by Region (2027-2032)
  15. 1.6 Assumptions and Limitations
  16. 1.7 Study Goals and Objectives
  17. 1.8 Years Considered
2 Global Hemophilia Gene Therapy Market Dynamics
  1. 2.1 Hemophilia Gene Therapy Industry Trends
  2. 2.2 Hemophilia Gene Therapy Industry Drivers
  3. 2.3 Hemophilia Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Hemophilia Gene Therapy Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Hemophilia Gene Therapy Revenue by Company (2021-2026)
  2. 3.2 Global Hemophilia Gene Therapy Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Hemophilia Gene Therapy Key Company Head office and Area Served
  4. 3.4 Global Hemophilia Gene Therapy Company, Product Type & Application
  5. 3.5 Global Hemophilia Gene Therapy Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Hemophilia Gene Therapy Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Hemophilia Gene Therapy Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Hemophilia Gene Therapy Tier 1, Tier 2, and Tier 3
4 Hemophilia Gene Therapy Market by Type
  1. 4.1 Global Hemophilia Gene Therapy Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Hemophilia Gene Therapy Market Size by Type (2021-2032)
  3. 4.3 Global Hemophilia Gene Therapy Market Size Share by Type (2021-2032)
5 Hemophilia Gene Therapy Market by Application
  1. 5.1 Global Hemophilia Gene Therapy Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Hemophilia Gene Therapy Market Size by Application (2021-2032)
  3. 5.3 Global Hemophilia Gene Therapy Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Spark Therapeutics
  2. 6.1.1 Spark Therapeutics Company Information
  3. 6.1.2 Spark Therapeutics Business Overview
  4. 6.1.3 Spark Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
  6. 6.1.5 Spark Therapeutics Recent Developments
  7. 6.2 Ultragenyx
  8. 6.2.1 Ultragenyx Company Information
  9. 6.2.2 Ultragenyx Business Overview
  10. 6.2.3 Ultragenyx Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
  12. 6.2.5 Ultragenyx Recent Developments
  13. 6.3 Shire PLC
  14. 6.3.1 Shire PLC Company Information
  15. 6.3.2 Shire PLC Business Overview
  16. 6.3.3 Shire PLC Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
  18. 6.3.5 Shire PLC Recent Developments
  19. 6.4 Sangamo Therapeutics
  20. 6.4.1 Sangamo Therapeutics Company Information
  21. 6.4.2 Sangamo Therapeutics Business Overview
  22. 6.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
  24. 6.4.5 Sangamo Therapeutics Recent Developments
  25. 6.5 Bioverativ
  26. 6.5.1 Bioverativ Company Information
  27. 6.5.2 Bioverativ Business Overview
  28. 6.5.3 Bioverativ Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
  30. 6.5.5 Bioverativ Recent Developments
  31. 6.6 BioMarin
  32. 6.6.1 BioMarin Company Information
  33. 6.6.2 BioMarin Business Overview
  34. 6.6.3 BioMarin Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
  36. 6.6.5 BioMarin Recent Developments
  37. 6.7 uniQure
  38. 6.7.1 uniQure Company Information
  39. 6.7.2 uniQure Business Overview
  40. 6.7.3 uniQure Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
  42. 6.7.5 uniQure Recent Developments
  43. 6.8 Freeline Therapeutics
  44. 6.8.1 Freeline Therapeutics Company Information
  45. 6.8.2 Freeline Therapeutics Business Overview
  46. 6.8.3 Freeline Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
  48. 6.8.5 Freeline Therapeutics Recent Developments
7 North America
  1. 7.1 North America Hemophilia Gene Therapy Market Size (2021-2032)
  2. 7.2 North America Hemophilia Gene Therapy Market Size by Type
  3. 7.2.1 North America Hemophilia Gene Therapy Market Size by Type (2021-2026)
  4. 7.2.2 North America Hemophilia Gene Therapy Market Size by Type (2027-2032)
  5. 7.2.3 North America Hemophilia Gene Therapy Market Share by Type (2021-2032)
  6. 7.3 North America Hemophilia Gene Therapy Market Size by Application
  7. 7.3.1 North America Hemophilia Gene Therapy Market Size by Application (2021-2026)
  8. 7.3.2 North America Hemophilia Gene Therapy Market Size by Application (2027-2032)
  9. 7.3.3 North America Hemophilia Gene Therapy Market Share by Application (2021-2032)
  10. 7.4 North America Hemophilia Gene Therapy Market Size by Country
  11. 7.4.1 North America Hemophilia Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Hemophilia Gene Therapy Market Size by Country (2021-2026)
  13. 7.4.3 North America Hemophilia Gene Therapy Market Size by Country (2027-2032)
  14. 7.4.4 North America Hemophilia Gene Therapy Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Hemophilia Gene Therapy Market Size (2021-2032)
  2. 8.2 Europe Hemophilia Gene Therapy Market Size by Type
  3. 8.2.1 Europe Hemophilia Gene Therapy Market Size by Type (2021-2026)
  4. 8.2.2 Europe Hemophilia Gene Therapy Market Size by Type (2027-2032)
  5. 8.2.3 Europe Hemophilia Gene Therapy Market Share by Type (2021-2032)
  6. 8.3 Europe Hemophilia Gene Therapy Market Size by Application
  7. 8.3.1 Europe Hemophilia Gene Therapy Market Size by Application (2021-2026)
  8. 8.3.2 Europe Hemophilia Gene Therapy Market Size by Application (2027-2032)
  9. 8.3.3 Europe Hemophilia Gene Therapy Market Share by Application (2021-2032)
  10. 8.4 Europe Hemophilia Gene Therapy Market Size by Country
  11. 8.4.1 Europe Hemophilia Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Hemophilia Gene Therapy Market Size by Country (2021-2026)
  13. 8.4.3 Europe Hemophilia Gene Therapy Market Size by Country (2027-2032)
  14. 8.4.4 Europe Hemophilia Gene Therapy Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Hemophilia Gene Therapy Market Size (2021-2032)
  2. 9.2 China Hemophilia Gene Therapy Market Size by Type
  3. 9.2.1 China Hemophilia Gene Therapy Market Size by Type (2021-2026)
  4. 9.2.2 China Hemophilia Gene Therapy Market Size by Type (2027-2032)
  5. 9.2.3 China Hemophilia Gene Therapy Market Share by Type (2021-2032)
  6. 9.3 China Hemophilia Gene Therapy Market Size by Application
  7. 9.3.1 China Hemophilia Gene Therapy Market Size by Application (2021-2026)
  8. 9.3.2 China Hemophilia Gene Therapy Market Size by Application (2027-2032)
  9. 9.3.3 China Hemophilia Gene Therapy Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Hemophilia Gene Therapy Market Size (2021-2032)
  2. 10.2 Asia Hemophilia Gene Therapy Market Size by Type
  3. 10.2.1 Asia Hemophilia Gene Therapy Market Size by Type (2021-2026)
  4. 10.2.2 Asia Hemophilia Gene Therapy Market Size by Type (2027-2032)
  5. 10.2.3 Asia Hemophilia Gene Therapy Market Share by Type (2021-2032)
  6. 10.3 Asia Hemophilia Gene Therapy Market Size by Application
  7. 10.3.1 Asia Hemophilia Gene Therapy Market Size by Application (2021-2026)
  8. 10.3.2 Asia Hemophilia Gene Therapy Market Size by Application (2027-2032)
  9. 10.3.3 Asia Hemophilia Gene Therapy Market Share by Application (2021-2032)
  10. 10.4 Asia Hemophilia Gene Therapy Market Size by Country
  11. 10.4.1 Asia Hemophilia Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Hemophilia Gene Therapy Market Size by Country (2021-2026)
  13. 10.4.3 Asia Hemophilia Gene Therapy Market Size by Country (2027-2032)
  14. 10.4.4 Asia Hemophilia Gene Therapy Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Hemophilia Gene Therapy Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Hemophilia Gene Therapy Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Hemophilia Gene Therapy Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Hemophilia Gene Therapy Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst